Track 2: Third Annual HDAC Inhibitors
Intercontinental Hotel Boston Massachusetts
Track 2: Third Annual HDAC Inhibitors
Cambridge Healthtech Institute

Schedule of Presentations:

Monday, November 2, 2009
07:00:00 Registration and Morning Coffee
07:05:00 Exploring Cellular Signaling Pathways and Mode-of-Action
08:30:00 Chairperson’s Opening Remarks
08:40:00 Targeting Histone Deacetylases in Non-Small Cell Lung Cancer Pran Datta
09:10:00 New Insights into the Mechanisms of HDAC Inhibitors Anti-Cancer Activity Roberto Rosato
09:40:00 Total Synthesis and Biological Mode of Action of Macrocyclic Histone Deacetylase Inhibitors Robert M. Williams
10:10:00 Grand Opening Coffee Break in the Exhibit Hall
10:40:00 Chemical Phylogenetics of Human Histone Deacetylases James E. Bradner
11:10:00 Anti-inflammatory Effects of HDACi Through Modulation of Foxp3+ Treg Functions Wayne Hancock
11:40:00 Utility of Predictive Biomarkers in the Clinical Development of the HDAC Inhibitor PCI-24781 Sriram Balasubramanian
12:10:00 Recent Advances in HDAC Biology Keynote Presentation: Eric M Verdin
12:40:00 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
14:20:00 Chairperson’s Remarks Joel M. Gottesfeld
14:25:00 Therapeutic Applications of Histone Acetylation-Independent Mechanisms of HDAC Inhibitors in Cancer Treatment Ching-Shih Chen
14:55:00 Design and Development of a Novel Series of HDAC Inhibitors for the Treatment of Cancer and Inflammation Stephen Shuttleworth
15:25:00 Development of Novel HDAC Inhibitors for CNS Indications Holger Patzke
15:55:00 Networking Refreshment Break in the Exhibit Hall
16:30:00 Histone Deacetylase Inhibitors as Therapeutics for Neurodegenerative Diseases Joel M. Gottesfeld
17:00:00 Sponsored Presentation (Sponsorship Opportunity Available)
17:15:00 Discovery and Pre-clinical Profile of Novel Potent HDAC Inhibitors Shridhar Narayanan
17:45:00 Happy Hour in the Exhibit Hall
19:00:00 Close of Day
Tuesday, November 3, 2009
07:30:00 Continental Breakfast Breakout Discussion Sessions
08:30:00 Chairperson’s Remarks Sriram Balasubramanian
08:40:00 Discovery of SB939, an HDAC Inhibitor with Class-Leading Properties Haishan Wang
09:10:00 Belinostat: A Pan HDAC Inhibitor with Clinical Potential in Both Hematological Malignancies and Solid Tumors Steven Butcher, Richard Penson
09:40:00 Networking Coffee Break in the Exhibit Hall
10:40:00 HDAC Inhibitor Entinostat Sensitizes ERa-negative MDA-MB-231 Tumors to Respond to Aromatase Inhibitor Letrozole Chaya Brodie
11:10:00 JNJ-26481585 – Development of a Novel Second Generation Oral Pan-HDAC Inhibitor for Anti-Cancer Therapy Janna Sand-Dejmek
11:40:00 A Clinical Update on the Development of Panobinostat Samit Hirawat
12:10:00 Improving Outcomes for Lung Cancer with HDAC Inhibitors Suresh Ramalingam
12:40:00 Close of Conference
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.